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ABSTRACT
Cancer stem cells (CSCs) play major roles in cancer initiation, metastasis, 
recurrence and therapeutic resistance. Targeting CSCs represents a promising strategy 
for cancer treatment. The purpose of this study was to identify selective inhibitors 
of breast CSCs (BCSCs). We carried out a cell-based phenotypic screening with cell 
viability as a primary endpoint, using a collection of 2,546 FDA-approved drugs and 
drug-like molecules in spheres formed by malignant human breast gland-derived cells 
(HMLER-shEcad cells, representing BCSCs) and control immortalized non-tumorigenic 
human mammary cells (HMLE cells, representing normal stem cells). 19 compounds 
were identified from screening. The chemically related molecules benztropine 
mesylate and deptropine citrate were selected for further validation and both potently 
inhibited sphere formation and self-renewal of BCSCs in vitro. Benztropine mesylate 
treatment decreased cell subpopulations with high ALDH activity and with a CD44+/
CD24- phenotype. In vivo, benztropine mesylate inhibited tumor-initiating potential in 
a 4T1 mouse model. Functional studies indicated that benztropine mesylate inhibits 
functions of CSCs via the acetylcholine receptors, dopamine transporters/receptors, 
and/or histamine receptors. In summary, our findings identify benztropine mesylate 
as an inhibitor of BCSCs in vitro and in vivo. This study also provides a screening 
platform for identification of additional anti-CSC agents.
INTRODUCTION
Breast cancer is the most common cancer in women 
worldwide, and is also the second leading cause of 
cancer death in women. Breast cancer patients are treated 
with cytotoxic, anti-hormonal and immunotherapeutic 
agents targeting HER-2 in the adjuvant, neoadjuvant 
and metastatic settings, depending on the molecular and 
biological characteristics of the cancer. However, drug 
resistance is a major problem [1] and increasing evidence 
indicates that a possible cause for treatment failure is the 
existence of cancer stem cells (CSCs) [2–6].
The CSC hypothesis proposes that a small 
subpopulation of slow-growing tumor cells have self-
renewal ability and drive tumorigenesis, progression and 
metastasis [7–11]. The differentiation ability of CSCs 
contributes to tumor cellular heterogeneity and it can 
give rise to a hierarchy of proliferative and progressively 
differentiating cells, which can generate the full repertoire 
of tumor cells including both tumorigenic cells and non-
tumorigenic cells [12]. From a therapeutic perspective, the 
selective targeting of CSCs could be an efficient approach 
to control cancer growth.
Several agents have been identified that may 
selectively target CSCs. Salinomycin exhibited inhibitory 
effects on epithelial-mesenchymal transition (EMT)-
induced breast cancer SCs and reduced the CD44+/CD24-
subpopulation [13]. Metformin, a first-line drug used 
for treating type II diabetes, was reported to selectively 
kill a chemotherapy-resistant subpopulation of CSCs 
in an in vivo breast cancer model [14]. Dasatinib may 
preferentially inhibit the growth of breast cancers with 
an EMT-stem cell-like phenotype, particularly of triple-
negative cancers of the basal-like subtype [15].
Due to the fact that the CSC subpopulations in 
tumors are very small, the collection of large numbers 
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of CSCs that can be used for drug screening is a great 
challenge. Different strategies have been applied to 
enrich CSCs, including cell sorting based on cell-surface 
markers [10], isolation of dye-exclusion side population 
cells [16, 17], sphere formation [18], resistance to 
chemotherapeutic compounds [3], EMT induction [19] 
and high activity of the intracellular enzyme aldehyde 
dehydrogenase (ALDH) [20, 21]. A combination of 
different methods for CSC enrichment may enrich for 
cancer cells at a higher level of cancer hierarchy and be 
more suitable for drug development [22].
The aims of the present study were to establish 
a simple, reliable and cost-efficient method to screen 
for selective CSC-targeting drugs and to identify drug 
candidates for further preclinical studies and potential 
clinical development. In an effort to derive sufficient 
CSCs for primary screening, we used EMT-induced 
CSCs (HMLER-shEcad cells) [13, 19] and applied the 
sphere culture technique to enrich CSCs further. We also 
used immortalized non-tumorigenic human mammary 
(HMLE cells) adherent cells and spheres as controls [19]. 
We screened a drug library containing FDA-approved 
compounds (Prestwick library) and a small chemical 
library with high structural and chemical diversity (NCI-
DTP diversity set II) to identify inhibitors of breast 
CSCs (BCSCs). We identified nineteen compounds that 
predominantly inhibited the growth of BCSC-enriched 
spheres, without major influence on normal stem cell 
-enriched spheres. One group of compounds with the 
same chemical core structure (benztropine mesylate and 
deptropine citrate) was identified and further analyzed 
with regard to the inhibition of functional properties of 
CSCs in vitro and in vivo.
RESULTS
Mammospheres generated from HMLER-
shEcad BCSCs
A major challenge in cell-based phenotypic 
screening is the limited number of CSCs in cancer 
cell cultures. To increase CSC numbers, we generated 
mammospheres from EMT-induced CSCs (HMLER-
shEcad cells) and examined whether this might further 
enrich CSCs compared to adherent culture conditions. 
CSCs mostly maintain quiescence or are slow-cycling 
[23]. The HMLER-shEcad spheres demonstrated 
a significant decrease in proliferation compared to 
adherent HMLER-shEcad cells (Supplementary Figure 
S1A; two-way ANOVA, p<0.001). HMLER-shEcad 
spheres also exhibited more resistance to both paclitaxel 
and doxorubicin than adherent HMLER-shEcad 
cells (Supplementary Figure S1B). ALDH is used as 
a biomarker to identify and characterize the BCSC 
phenotype [24]. FACS data indicated a higher percentage 
of ALDH+ cells in HMLER-shEcad spheres than that in 
adherent cells (sphere vs adherent cells: 6.4±1.01% vs 
1.5±0.155%, p<0.01) (Supplementary Figure S1C-D). 
Gene expression measurements by qRT-PCR showed 
that expression of BCSC related genes, including CD44, 
ALDH1, CD133, SLUG, FOXC2 and OCT4 was increased 
in HMLER-shEcad spheres compared with the adherent 
cells (Supplementary Figure S1E and Supplementary 
Table S1).
Identification of compounds with specific 
inhibition of spheroid CSCs via cell-based 
phenotypic screening
The above results confirmed that a subpopulation 
of cells with CSC properties became enriched during 
mammosphere formation. Therefore, we hypothesized 
that compounds with a selective inhibition of the HMLER-
shEcad spheres might have inhibitory activity on CSCs. 
For the compound library screening, we first cultured 
HMLE cells and HMLER-shEcad cells in suspension 
with SCM to generate sufficient spheres for screening. 
The primary spheres were dissociated and used to generate 
subsequent sphere generations, which were used in the 
screening platform (from the third to the fifth generation). 
Cells from each cell line were seeded in 96-well plates, 
allowed to proliferate for 24 h, treated with the compounds 
of the chemical libraries at 10 µM, and assayed for cell 
viability after 3 days of incubation (Figure 1A). The 
screening of 2,546 small molecules was done in two 
independent experiments with a very high inter-assay 
correlation (Figure 1B–1C, r>0.7). Thus, the protocol 
enabled consistent generation of high quality sample spots, 
which was necessary to ensure that sufficient precision in 
determining deficient samples was achieved and the risk of 
producing false negative hits was minimized.
Approximately 6.0% (152 of 2,546) of the test 
compounds reduced the viability of HMLER-shEcad 
spheres by more than 50% (Figure 1D–1E). Out of 
these, nine compounds from the NCI-DTP diversity 
Set II (hit ratio: 0.66%) (Figure 1F) and ten compounds 
from the Prestwick library decreased the viability of 
control HMLE spheres by 30% or less (hit ratio: 0.80%) 
(Figure 1G). Among these nineteen hits, three groups of 
compounds with the same chemical core structures were 
identified. NSC42199 (from NCI-DTP diversity Set II) 
and Prestw-1236 (from Prestwick library) are benztropine 
mesylate. Prestw-1013 (deptropine citrate) and benztropine 
mesylate share the same chemical core structure 
(diphenylmethane), as do Prestw-389 (ketoconazole) and 
Prestw-1229 (aripiprazole) (phenylpiperazine), as well as 
Prestw-899 (adrenosterone) and NSC27592 (tomatidine) 
(dimethyldecahydronaphthalene) (Figure 2A). Cell 
viability was further assessed over a wide range of doses 
to calculate the half-maximal inhibitory concentration 
(IC50) for each compound. The dose-response curves 
demonstrated that the cell viability of HMLER-shEcad 
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Figure 1: Chemical screening for compounds that selectively inhibit the viability of HMLER-shEcad spheres. A. 
Schematic overview of the chemical library screening strategy. B-C. Replicate correlation plots of raw values from two replicates of the 
same compounds in HMLE and HMLER-shEcad adherent cells and spheres, respectively, showing good agreement and suggesting overall 
good reproducibility. D-E. Summary of the cell viability of HMLE and HMLER-shEcad spheres, with all compounds from NCI-DTP 
diversity set II and Prestwick library. F-G. Nineteen candidate compounds were identified by chemical library screening based on cell 
viability assays.
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Figure 2: Identification and validation of compounds that exhibit selective inhibitory effects on HMLER-shEcad 
spheres. A. Three groups of active compounds with related chemical core structures were identified: Group 1: deptropine (Prestw-1013: 
deptropine citrate) and benztropine (NSC42199/Prestw-1236: benztropine mesylate); Group 2: adrenosterone (Prestw-899) and tomatidine 
(NSC27592); Group 3: aripiprazole (Prestw-1229) and ketoconazole (Prestw-389) B. Dose-response curves of HMLE spheres and 
HMLER-shEcad spheres treated with selected compounds. C. Cell viability of MDA-MB-231 spheres treated with different concentrations 
of deptropine citrate and benztropine mesylate for 72 h. Data are expressed as mean±SD.
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spheres was inhibited more potently than that of HMLE 
spheres using the selected compounds (Figure 2B).
Considering the fact that NSC42199 (benztropine 
mesylate, from NCI-DTP diversity Set II), Prestw-1013 
(deptropine citrate) and Prestw-1236 (benztropine 
mesylate from Prestwick library) were identified from two 
different libraries, as well as their preferential inhibitory 
effects on HMLER-shEcad spheres, we focused our 
investigations on these compounds. We next investigated 
their effects on the cell viability of spheres induced from 
two other CSC-enriched breast cancer cell lines, namely 
human MDA-MB-231 cells and murine 4T1-luc2 cells 
[25, 26]. The IC50 values of benztropine mesylate and 
deptropine citrate for MDA-MB-231 spheres were ~5 
µM (Figure 2C). For 4T1-luc2 spheres, the IC50 value of 
benztropine mesylate was around 5 µM (Supplementary 
Figure S2).
Deptropine citrate and benztropine mesylate 
suppress mammosphere formation and self-
renewal capacities of BCSCs in vitro
The ability to form mammospheres is correlated 
with the frequency of CSCs and progenitor cells in 
tumor cell lines. Thus, we next analyzed the effects 
of different concentrations of deptropine citrate and 
benztropine mesylate on mammosphere formation of 
MDA-MB-231 and 4T1-luc2 cells. Paclitaxel served 
as a conventional chemotherapy drug control, whereas 
salinomycin served as a positive control for selectively 
targeting CSCs [13]. The mammosphere growth in SCM 
with or without compounds was observed after 6 days. In 
MDA-MB-231 cells, deptropine citrate and benztropine 
mesylate reduced the size as well as the number of 
mammospheres significantly in a dose-dependent manner 
(Figure 3A and Supplementary Figure S3A, p<0.001). In 
4T1-luc2 cells, treatment with 5 or 10 µM, but not 1 µM, 
of the compounds had a significant inhibitory effect on 
the number and size of the mammospheres (Figure 3B 
and Supplementary Figure S3B, p<0.001). In contrast, 
paclitaxel had no major effect on the number of spheres in 
both cell lines (Figure 3A–3B). The same effect was also 
found in HMLER-shEcad (data not shown). The inhibitory 
effects of different concentrations of the compounds on 
sphere formation corresponded to their effects on cell 
viability (Supplementary Figure S3C-D).
The ability of self-renewal is a unique characteristic 
of stem cells. We tested the ability of MDA-MB-231 
cells and 4T1-luc2 cells to form subsequent sphere 
generations in suspension (without treatment) after a 4-day 
pretreatment of the cells with the selected compounds 
under adherent conditions. The sphere forming efficiency 
of MDA-MB-231 cells in different generations was 
markedly suppressed by pretreatment with 5 µM 
deptropine citrate and benztropine mesylate, as compared 
to DMSO (Figure 3C). Moreover, a significant inhibitory 
effect on sphere formation by 5 µM benztropine mesylate 
was maintained even in the quaternary spheres, suggesting 
that treatment with benztropine mesylate reduced the stem 
cell-like subpopulation, and thus prevented the recovery of 
sphere formation (Figure 3C). A similar effect was seen for 
the sphere formation of 4T1-luc2 cells after pretreatment 
with the compounds (Figure 3D). Thus, the compounds 
had an apparent effect on the self-renewal capability of 
breast cancer cells, which persisted after drug withdrawal. 
Salinomycin potently inhibited sphere formation of both 
cell lines in all generations, whereas paclitaxel showed 
inhibition in MDA-MB-231 cells but not in 4T1-luc2 cells.
Benztropine mesylate decreases the percentage 
of breast cancer cells expressing CSC markers
In light of the above data, we focused further on the 
anti-CSC properties of benztropine mesylate. To confirm 
that benztropine mesylate targets the CSC subpopulation, 
we analyzed the expression of the prospective BCSC 
marker combination CD44+/CD24- and of ALDH after 
benztropine mesylate treatment. Incubation with different 
concentrations of benztropine mesylate resulted in a dose-
dependent reduction of the cell percentage with high 
ALDH activity in MDA-MB-231 spheres, SKBR3 cells 
and 4T1-luc2 cells (Figure 3E–3F and Supplementary 
Figure S4). The proportion of ALDH+ cells was 11.1% 
in the DMSO-treated group, and it decreased to 7.1, 5.5 
and 4.9% after 6 days treatment with 1, 5 and 10 µM 
benztropine mesylate, respectively (Figure 3E–3F). In 
contrast, paclitaxel (10 nM) increased the percentage 
of ALDH+ cells (Figure 3F; 16.8±1.28%, p<0.001). 
The percentage of the CD44+/CD24- subpopulation was 
significantly decreased when MDA-MB-231 spheres were 
exposed to 5 µM (20.0±12.64%) and 10 µM benztropine 
mesylate (13.3±13.36%) for 6 days, compared to DMSO-
treated cells (46.5±3.30%, p<0.01, n=3) (Figure 3G–3H). 
Salinomycin significantly reduced the CD44+/CD24-
subpopulation to 11.3% (±2.21%, p<0.001), whereas 
paclitaxel had no influence on the percentage of the 
CD44+/CD24- subpopulation in MDA-MB-231 spheres 
(42.5±3.28%, p>0.05).
Benztropine mesylate improves the efficiency of 
chemotherapy in vitro
Accumulating evidence indicates that CSCs are 
largely chemotherapy-resistant [3]. It has been proposed 
that combined chemotherapy and anti-CSC treatment may 
improve the efficacy of standard chemotherapy [2]. To 
investigate this hypothesis, 1,000 4T1-luc2 cells or MDA-
MB-231 cells were grown in suspension with SCM in the 
presence of 10 nM paclitaxel alone, 5 µM benztropine 
mesylate alone or both drugs combined. After 6 days, 
compared to DMSO (sphere number/well: 4T1-luc2 
spheres: 50.0±6.45; MDA-MB-231 spheres: 55.3±6.83) or 
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Figure 3: Inhibitory effects of benztropine mesylate on BCSC properties in vitro. A-B. Mammosphere formation 
assays: Number of mammospheres (diameter > 50 μm) from 1,000 MDA-MB-231 or 4T1-luc2 cells which were treated with different 
concentrations of deptropine citrate, benztropine mesylate, salinomycin or paclitaxel for 6 days was counted. C-D. Self-renewal assays: 
Adherent cells were pretreated with or without the compounds at indicated concentrations for 4 days and mammosphere formation was 
evaluated in sequential sphere generations without any treatment. Data are expressed as mean±SD (n=6). FACS analysis of the expression 
of CSC markers (ALDH+ and CD44+/CD24-) in MDA-MB-231 spheres with or without benztropine mesylate treatment. MDA-MB-231 
spheres were treated with benztropine mesylate (1, 5 or 10 µM), salinomycin (2 µM), paclitaxel (10 nM) or DMSO for 6 days. Single cell 
suspensions were used for FACS analysis. Representative data for ALDH+ E. and CD44+/CD24- G. populations in benztropine mesylate-
treated MDA-MB-231 spheres show a reduction compared with DMSO-treated cells. DEAB was used to inhibit the reaction of ALDH with 
the ALDEFLUOR reagent, providing a negative control. The proportions of ALDH+ F. and CD44+/CD24- H. cells are shown as mean±SD. 
Experiments (n=3) were conducted in triplicate. **p<0.01, ***p<0.001 compared with DMSO control (one-way ANOVA).
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paclitaxel (4T1-luc2 spheres: 47.5±4.76; MDA-MB-231 
spheres: 57.5±7.18), the combination treatment inhibited 
the sphere formation significantly (4T1-luc2 spheres: 
11.3±2.34; MDA-MB-231 spheres: 10.7±2.73; p<0.001). 
Compared to benztropine mesylate alone (MDA-MB-231 
spheres: 22.8±6.27), the combination treatment decreased 
sphere formation efficiency by 53.1% in MDA-MB-231 
spheres (p<0.05, Figure 4A-4B).
We next pretreated adherent 4T1-luc2 cells or MDA-
MB-231 cells with 10 nM paclitaxel alone or combined 
with 5 µM benztropine mesylate for 4 days and performed 
mammosphere formation assays. Compared to DMSO 
(sphere number/well: 55.0±6.07) or paclitaxel (51.8±6.40) 
alone, the combination treatment significantly reduced 
the sphere formation of 4T1-luc2 cells (0.50±0.548), 
which was more efficient than benztropine mesylate 
alone (8.33±3.50, p<0.05). For MDA-MB-231 cells, 
both benztropine mesylate alone (sphere number/well: 
20.7±4.41) and the combination treatment (15.8±2.93) 
impaired the sphere formation by >57%, compared to 
DMSO (47.8±4.54) and paclitaxel alone (46.5±1.23, 
p<0.001). There was no significant difference between 
benztropine mesylate and combination treatment (Figure 
4C–4D).
Benztropine mesylate inhibits tumor-initiating 
potential in vivo
To test whether benztropine mesylate might 
have any anti-CSC activity in vivo, we used the gold-
standard assay for CSCs, the limiting dilution assay. 
4T1 spheres were maintained in SCM and treated 
with benztropine mesylate or DMSO in vitro for 6 
days. Single cell suspensions isolated from pretreated-
spheres were prepared and injected in serial limiting 
dilutions (10 - 1,000 cells) into Balb/c mice, which 
were monitored for subsequent tumor formation for 
four weeks. We observed that benztropine mesylate 
pretreatment resulted in a significant reduction in 
the tumor-initiating potential relative to the DMSO 
group (Table 1). We further performed an ELDA 
(extreme limiting dilution assay) to evaluate the effect 
of benztropine mesylate on the CSC frequency. The 
repopulating frequency of CSCs was 1 of 218 for 
benztropine mesylate treatment and 1 of 9 for DMSO 
control in 4T1 cells. The difference in CSC frequency 
between the two groups was significant (p<0.001, 
Table 1). We next treated Balb/c mice bearing 4T1 
breast tumors with benztropine mesylate (1.5 mg/kg) 
or 0.9% saline for 3 weeks. Both tumor size and tumor 
weight were significantly reduced after benztropine 
mesylate treatment, as compared to the saline treated 
control group (Supplementary Figure S5A-B). There 
was no difference in body weight between the treatment 
groups (Supplementary Figure S5C).
Benztropine mesylate partially inhibits the CSC 
properties through acetylcholine receptors, 
dopamine transporters/receptors and/or 
histamine receptors
Benztropine mesylate is used clinically for 
the management of Parkinson’s disease and its 
pharmacological effects are thought to result from its 
anticholinergic activity [27]. However, benztropine 
mesylate is also a centrally acting anti-histamine [28] and 
dopamine re-uptake inhibitor [29]. To determine which, 
if any, of these activities play a role in the inhibition of 
CSC properties, we evaluated the ability of selective 
agonists of muscarinic acetycholine receptors (mAChRs), 
nicotinic acetylcholine receptors (nAChRs) (carbachol), 
dopamine receptors (dopamine) or histaminergic receptors 
(histamine) to reduce the inhibitory activity of benztropine 
mesylate on mammosphere formation of BCSCs. The 
benztropine mesylate-induced inhibition of mammosphere 
formation in 4T1-luc2 cells was significantly reduced 
in the presence of carbachol, histamine and dopamine, 
as well as after combination treatment (Figure 5A–5C, 
p<0.01). Carbachol and histamine also significantly 
reduced the inhibitory effect of benztropine mesylate 
on MDA-MB-231 sphere formation (Supplementary 
Figure S6A-S6B, p<0.05). The combination treatment 
with carbachol, histamine and dopamine partially but not 
completely blocked the inhibitory effects of benztropine 
mesylate on mammosphere formation of BCSCs.
We then evaluated a panel of antagonists for these 
receptors, including the dopamine receptor antagonist 
haloperidol, the histaminergic receptor antagonist 
pyrilamine, and the acetylcholine receptor antagonists 
atropine, hexamethonium bromide and pancuronium on 
mammosphere formation of 4T1-luc2 cells (Figure 5D–5E 
and Supplementary Figure S6C-S6E) and MDA-MB-231 
cells (Supplementary Figure S6F-S6J). We found that 10 
µM of haloperidol inhibited mammosphere formation of 
4T1-luc2 cells. The mammosphere formation of MDA-
MB-231 cells was also significantly reduced when cells 
were incubated with 10 nM of pyrilamine or different 
doses of haloperidol (500 nM, 1 and 10 µM).
To further probe the potential mechanisms of action, 
we applied the SPiDER protocol [30]. The software 
successfully ranked known on- and off-targets of the 
compound among the high confidence predictions (p<0.05, 
Table S2). These results suggest that neurotransmitter 
receptors may play important roles for the inhibitory 
effects of benztropine on BCSCs (nicotinic acetylcholine 
receptor agonist: p=0.005; muscarinic acetylcholine 
receptor antagonist: p=0.023; histamine receptor: p=0.016; 
dopamine receptor antagonist: p=0.03).
In a next step, we determined the mRNA expression 
levels of distinct acetylcholine receptors in sphere-
forming and adherent HMLER shEcad, HMLER shCtrl 
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Figure 4: Benztropine mesylate treatment improves the efficiency of chemotherapy in vitro. A. Schematic representation 
of the experimental approach taken to quantify the mammosphere formation efficiency of 4T1-luc2 and MDA-MB-231 cells by 
combination treatment with benztropine mesylate (5 µM) and paclitaxel (10 nM) or as single agent treatment. B. Representative images 
and quantification of mammosphere numbers after 6 days. C. Schematic representation of the experimental approach taken to quantify 
the mammosphere formation efficiency of pretreated-4T1-luc2 cells and MDA-MB-231 cells by combination treatment with benztropine 
mesylate and paclitaxel or by single agent treatment. D. Representative images and quantification of mammosphere numbers after 6 
days. Data are expressed as mean±SD (n=6). ***p<0.001 compared with DMSO control (one-way ANOVA); #p<0.05 compared with 
benztropine mesylate group.
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and HMLE cells. We found that the mRNA expression 
levels of α2-nAChR (CHRNA2), α5-nAChR (CHRNA5), 
α6-nAChR (CHRNA6), α9-nAChR (CHRNA9), α10-
nAChR (CHRNA10) and β1-nAChR (CHRNB1) were 
higher in HMLER shEcad than in HMLER shCtrl cells 
(CHRNA5: >4-fold; CHRNA9: >12-fold; CHRNB1: 
>4-fold; CHRNA2, 6 and 10: ~2-fold) (Supplementary 
Figure S7A). The expression of CHRNA9 was 17.4-fold 
higher in sphere-forming HMLER shEcad cells than in 
adherent HMLER shEcad cells (Supplementary Figure 
S7B). Importantly, CHRNA9 mRNA was more strongly 
expressed (126.8-fold) in HMLER shEcad spheres 
than in immortalized, non-tumorigenic HMLE spheres 
(Supplementary Figure S7C).
DISCUSSION
The existence of CSCs has been reported across 
a range of hematological as well as solid malignancies, 
and these cells display the capacity for self-renewal and 
differentiation, which are critical for tumor initiation, 
progression, metastasis and recurrence [31]. The CSC 
model not only provides an explanation for the failure 
of conventional cancer therapies that target proliferating 
tumor cells, but also provides an important drug target in 
cancer [3, 4, 8]. Identification of agents that selectively 
inhibit the traits of BCSCs has therefore become a key 
goal in the challenge to improve the efficacy of cancer 
therapy.
In the present study, we screened two small 
molecule libraries by using a 96-well plate spheroid-
derived CSC growth assay. We used HMLER-shEcad 
spheres as a model for CSCs. It has been previously 
shown that HMLER-shEcad cells are enriched with EMT-
induced CSCs. These cells are transformed to have a 
mesenchymal phenotype (a hallmark of CSCs) by down-
regulation of E-cadherin, producing a high percentage of 
a CD44+/CD24- population [19]. Dontu et al. indicated 
that suspension mammospheres are enriched in early 
progenitor/stem cells and are able to differentiate and 
generate complex functional structures in a reconstituted 
3D-culture system with SCM [18]. Our study combined 
the two CSC enrichment methods and generated HMLER-
shEcad spheres. We found that HMLER-shEcad spheres 
showed a higher population of slow-cycling cells, a higher 
percentage of cells with high ALDH activity and increased 
chemotherapy-resistance, compared with HMLER-shEcad 
adherent cells. These results indicated that HMLER-
shEcad spheres contained a higher proportion of BCSCs. 
Additionally, HMLER-shEcad cells cultured under 
adherent conditions in differentiation medium showed a 
cellular hierarchy with tumorigenic and non-tumorigenic 
cells, which is an important character of CSCs. Based 
on CD44 and CD24 expression profiles, distinct cell 
populations of HMLER-shEcad cells were identified by 
FACS (data not shown), and previous studies found that 
the tumorigenic properties of distinct populations with 
distinct CD44 and CD24 phenotypes were different [10].
Several investigators have aimed to identify 
compounds that specifically inhibit the CSC-related 
molecular properties or kill CSCs directly. For example, 
Marx et al. screened the NCI-DTP diversity set II library 
and identified four compounds capable of selective 
silencing ErB2 transcription in breast cancer cells [32]. 
Three inhibitors (loxapine, pimozide and acacetin) of 
the ABC transporters (ABCB1, ABCC1 and ABCG2 
transporters), which are highly expressed in chemoresistant 
CSCs, were identified by high-throughput FACS screening 
of the Prestwick library [33]. Sun et al. performed a cell-
based screening using the Prestwick library to identify 
potential inhibitors of survivin in prostate cancer cells; 
survivin is a broadly expressed tumor antigen associated 
with CSCs [34]. Because CSC populations are very 
complex and multiple CSC pools exist within individual 
tumors [35], we designed the screening platform based on 
the function of CSCs, instead of just based on a single 
CSC-related molecular property.
A major challenge for high-throughput screening is 
to isolate and scale up sufficient amounts of CSCs. Other 
CSC enrichment methods based on cell surface markers, 
Hoechst dye exclusion, or cell auto-fluorescence, are 
often time- and money-consuming. It is also unclear 
whether any of these approaches can be used reliably and 
routinely to enrich CSCs across all subtypes. The spheroid 
Table 1: Tumor incidence in limiting dilution assay
Tumor incidence/injection
Cells Injected 1,000 100 10 Estimated cancer stem cell 
frequency with confidence 
intervals (95%)
4T1-DMSO 10/10 10/10 7/10 1 in 9 (4-18)
4T1-Benztropine mesylate 8/10 7/10 5/10 1 in 218 (100-479)***
4T1-luc2 spheres pretreated with benztropine mesylate or DMSO were dissociated into single-cell suspensions and injected 
into the mammary fat pads of mice in limiting dilution (10; 100; 1,000). Tumor formation was observed for four weeks 
following inoculation. BCSC frequency was calculated using ELDA.
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technique used here allows the production of large 
amounts of CSCs and therefore enables the availability of 
these cells for screening. Additionally, this assay allows 
the exclusion of compounds that inhibit not only CSCs, 
but also NSCs, since NSCs share many properties with 
CSCs. In fact, salinomycin was found to inhibit BCSC 
properties but it also exhibited equal toxicity to NSCs 
in vitro, with potential implications for its safety profile 
[36]. To validate the selectivity of candidate compounds 
for CSCs, we used HMLE adherent cells and spheres as 
Figure 5: Benztropine mesylate partially impairs mammosphere formation of breast CSCs through acetylcholine 
receptors, dopamine receptors/transporters and histamine receptors. Representative images A. and quantification of mammosphere 
formation efficiency B. of 1,000 4T1-luc2 cells co-treated with benztropine mesylate (5 µM) and dopamine (10 µM), histamine (5 µM) or 
carbachol (5 µM) alone or with an agonist combination (dopamine + histamine + carbachol) for 6 days. Quantification of mammosphere 
numbers from 1,000 4T1-luc2 cells treated with either the muscarinic receptor antagonist atropine D. or the dopamine receptor antagonist 
haloperidol E. for 6 days. Data are expressed as mean±SD (n=6). **p<0.01, ***p<0.001 compared with DMSO control (One-way ANOVA).
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controls, which contain distinctive and discrete naturally 
present subpopulations of stem-like and non-stem-like 
cells [19, 37]. Both HMLE adherent cells and spheres 
control conditions were used to eliminate compounds 
with general toxicity for normal breast cells and stem 
cell-like cells as well as to eliminate the compounds with 
inhibitory effects due to the suspension culture system. In 
summary, this model provides a convenient strategy for 
compound screening, but there are also some limitations: 
As the model is a specialized screening system and does 
not represent a specific type of breast cancer, further 
functional assays using defined human or mouse breast 
cancer cell lines are needed for confirmation of the 
screening results.
We used a small-molecule collection consisting of 
2,546 compounds from two chemical libraries including 
the NCI-DTP diversity set II and the Prestwick library 
for screening. The NCI-DTP diversity set II is an 
uncharacterized compound library, which provides the 
possibility of identifying novel lead candidates, with the 
drawback that the active mechanisms of these compounds 
are largely unknown. In contrast, the compounds from 
the Prestwick library are already FDA-approved, well-
characterized drugs, which may render the translation 
of discoveries from the basic laboratory to the clinical 
application more easily. Also, the already known 
mechanisms of action of the potential hit compounds may 
provide some hints for the exploration of the mechanism 
of their new function.
Based on this robust cell-based screening method, 
we identified nineteen compounds, including three groups 
of compounds with related chemical core structures, 
preferentially targeting the viability of HMLER-shEcad 
spheres but not HMLE adherent cells and spheres. 
We focused on characterizing the anti-CSC properties 
of the compounds deptropine citrate and benztropine 
mesylate, which have the same chemical core structure. 
Deptropine citrate, a well-known H1-histamine receptor 
antagonist and muscarinic receptor antagonist, showed 
inhibitory effects on cell viability and mammosphere 
formation of BCSCs, but it did not inhibit the self-renewal 
capacities of MDA-MB-231 cells. Benztropine mesylate 
significantly inhibited mammosphere formation and self-
renewal of BCSCs. It also decreased the ALDH+ and 
CD44+/CD24- CSC subpopulations. Previous studies 
showed that these markers both enrich for stem cells, 
however the populations do not appear to correlate 
highly with each other [38, 39]. Our results indicated that 
benztropine mesylate could inhibit CSCs with distinct 
phenotype. Additionally, our in vivo studies revealed 
that benztropine mesylate inhibited the tumor-initiating 
potential significantly and decreased the CSC frequency. 
Thus, benztropine mesylate is a potential anti-CSC drug 
candidate that can alter tumorigenic properties. However, 
considering the complexity and heterogeneity of human 
cancers, many preclinical animal models fail to predict 
the clinical efficacy of novel anti-cancer agents. Further 
functional research studies using humanized mouse 
models, such as patient-derived xenograft models [40] 
or mice with humanized immune system or mammary 
microenvironment [41] would be helpful to support a 
potential clinical translation.
Benztropine mesylate is a centrally acting 
anticholinergic agent for the treatment of Parkinson’s 
disease [27]. In a multiple sclerosis mouse model, 
benztropine mesylate induced the differentiation of 
oligodendrocytes through M1 and M3 muscarinic 
receptors and enhanced re-myelination [42]. Benztropine 
mesylate also acts as an anti-histamine [28] and a 
dopamine re-uptake inhibitor [29], and as an allosteric 
antagonist of the human D2 dopamine receptor 
(Pubchem BioAssay: AID 485344). In the present study, 
the pharmacological data indicated that benztropine 
mesylate partially inhibited the BCSC properties through 
acetylcholine receptors, dopamine receptors/transporters 
and/or histamine receptors, even though more detailed 
follow-up studies might be needed to investigate the 
relative contribution of these pathways. A previous study 
reported that thioridazine, an antagonist of the dopamine 
receptor, impairs human somatic CSCs capable of in vivo 
leukemic disease initiation by inducing differentiation to 
overcome neoplastic self-renewal, while having no effect 
on normal blood stem cells [43]. Haloperidol, which 
exhibits high affinity dopamine D2 receptor antagonism 
and slows receptor dissociation kinetics [44], inhibited 
mammosphere formation of BCSCs markedly in our study. 
Thus, our findings further indicate that dopamine receptors 
play an important role in mediating BCSC functions, and 
indicate that dopamine receptors might represent potential 
CSC markers in breast cancer. Further investigation is 
required to better understand the connection of dopamine 
receptor signaling and CSC biology in human cancers. 
The comparison of acetylcholine receptor expression 
levels indicates that CSCs have increased acetylcholine 
receptor expression levels, rendering them more sensitive 
to inhibition by benztropine mesylate. Future studies are 
needed to dissect the specific role of α9-nAChR for the 
biological properties of CSCs.
Other, yet unidentified pathways might also be 
involved in the anti-CSC effects of benztropine mesylate. 
A preliminary analysis of the topological pharmacophore 
feature pattern (CATS2 descriptor) [45] of benztropine 
mesylate suggested potential activity as a CCR5 
antagonist. Increasing evidence indicates that CCL5 and 
CCR5 are overexpressed in breast cancer, and CCR5 
antagonists block metastasis of breast cancer [46, 47]. 
However, in the DRUGMATRIX screen (https://ntp.niehs.
nih.gov/drugmatrix), benztropine mesylate was reported to 
not posses a high-affinity effect on CCR5 (<50% inhibition 
at 10 μM ligand concentration). The algorithm analysis 
by SPIDER software suggested that the compound could 
be modulating the Akt or Wnt pathways (through Akt or 
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Casein Kinase 1 binding, p=0.04, Table S2), which are 
associated with BCSCs [48–50]. This theoretical analysis 
points to motivated macromolecular targets of benztropine 
mesylate in the context of cancer, which deserve further 
attention.
CONCLUSIONS
Selective targeting of CSCs offers promise for a 
new generation of cancer therapeutics. In this study, we 
developed a cell-based phenotypic screening platform for 
the identification of CSC-specific inhibitors that have only 
minor effects on normal stem cells. Benztropine mesylate 
was identified as a novel potential anti-CSC inhibitor 
by in vitro and in vivo assays, thus revealing a novel 
usage for a known drug that could be readily translated 
to further preclinical and clinical development. The 
screening platform established here could also be applied 
for larger-scale screens for the identification of anti-CSC 
compounds.
METHODS
Cell lines, monolayer and mammosphere culture
HMLE and HMLER-shEcad cell lines were kindly 
provided by Dr. Robert Weinberg (MIT, Cambridge, MA, 
USA) on October 18, 2011, and were cultured as described 
[13, 51]. The cells were not authenticated afterwards. The 
MDA-MB-231 cell line was kindly provided by Dr. Nancy 
E. Hynes, FMI, Basel, Switzerland on July 24, 2011, 
and tested negative for mycoplasma with MycoProbe 
(R&D Systems). Cell line authentication was confirmed 
by short tandem repeat analysis on November 29, 2013, 
at Microsynth AG to match the fingerprint of the ATCC 
corresponding cell line. The 4T1-luc2 cell line was 
purchased from Calliper Life Science (Waltham, MA) 
on November 18, 2008, and no further authentication 
was done. Both cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco) with 10% fetal 
bovine serum (FBS, Invitrogen) and 1% (v/v) antibiotic-
antimycotic solution.
Mammospheres were generated by incubating single 
cell suspensions in serum-free stem cell medium (SCM) 
containing Mammary Epithelial Cell Growth Medium 
(MEGM, Lonza, for HMLE and HMLER-shEcad spheres) 
or Dulbecco’s Modified Eagle Medium: Nutrient Mixture 
F-12 (DMEM/F12, Gibco, for MDA-MB-231 and 4T1-
luc2 spheres) supplemented with 2% (v/v) B27 (Gibco), 
20 ng/ml epidermal growth factor (EGF, Peprotech Inc.), 
20 ng/ml basic fibroblast growth factor (bFGF, Peprotech 
Inc.), 10 µg/ml insulin, 20 µg/ml hydrocortisone (Sigma-
Aldrich) and antibiotic-antimycotic solution as described 
[13, 51] in flasks coated with poly (2-hydroxyethyl 
methacrylate) (poly-HEMA, Polysciences Inc.) solution. 
The spheres were passaged every 7-9 days.
Chemical libraries and reagents
Two commercially available chemical 
libraries, the Prestwick chemical library (http://www.
prestwickchemical.com/) and the NCI-DTP diversity Set II 
https://dtp.cancer.gov/databases_tools/data_search.htm 
were used. Compounds were solubilized at 1 mM in 
dimethyl sulfoxide (DMSO) and all compounds were 
diluted in assay media for a final concentration of 10 μM 
in the screen. The concentration of DMSO in each assay 
well, including all control wells was 1%. NSC42199 was 
kindly provided by the NCI/NIH, while Prestw-1013 and 
Prestw-1236 were purchased from Prestwick Chemical 
Inc. All other compounds used in in vitro assays were 
bought from Sigma and dissolved in DMSO.
Chemical screening and data analysis
The chemical screening was performed in a 96-
well plate format. 1,000 cells isolated from HMLE and 
HMLER-shEcad cells were inoculated in a mixed medium 
of MEGM and DMEM at adherent conditions, while 
3,000 sphere-forming cells isolated from related spheres 
were grown in SCM as suspension. After 24 h, cells were 
treated with compounds from the chemical libraries at 
10 µM or DMSO only. Cell viability was determined 
by the cell counting kit-8 (CCK-8) assay after 72 h 
treatment according to the manufacturer’s instructions. 
The optical density (OD) at 450 nm was measured by a 
microplate reader (Tecan Inc). The cell viability fraction 
(%) was calculated as follows: OD450nm-test compound / 
OD450nm-DMSO × 100%. The screening was done for two 
independent replicates and the quality of the experiments 
was determined by principal component analysis and 
calculation of the Pearson correlation coefficients (r) of 
biological replicates using Prism 5.0.
Chemotherapy sensitivity assays
1,000 cells were seeded in 96-well plates, and 
various concentrations of paclitaxel or doxorubicin were 
added after 24 h, and co-incubated for 72 h. The cell 
viability was measured using the CCK-8 assay.
Flow cytometry (FACS) analysis for CD44 and 
CD24
All antibodies were obtained from BD Biosciences 
(San Diego, CA, USA). Combinations of fluorochrome-
conjugated monoclonal antibodies against human CD44 
(APC; cat. # 559942) and CD24 (PE; cat. # 555428) or 
their respective isotype controls (APC mouse IgG2b,κ: cat. 
#555745; PE mouse IgG2a,κ: cat. #555574) were added to 
single cell suspensions of MDA-MB-231 spheres at 1:20 
and incubated at 4°C for 30 min. The labeled cells were 
washed in FACS buffer (2 mM EDTA, 1% (w/v) BSA in 
PBS) twice, and then acquired with a FACS Canto (BD 
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Biosciences). Data were analyzed with Flow Jo software 
(FlowJo X 10.0.7) and illustrated as percentage of cells 
with a CD44+/CD24- phenotype±SD.
Aldefluor assay
The ALDEFLUOR assay (STEMCELL 
Technologies) was used to profile stem and progenitor cells 
based on their high expression of ALDH1. The Aldefluor 
assay was conducted according to the manufacturer’s 
instructions. Briefly, single cell suspensions from treated 
or untreated tumor cells were harvested, washed with 
Aldefluor assay buffer, the cell density was adjusted to 106 
cells/ml in Aldefluor assay buffer supplement with ALDH 
substrate and cells were incubated for 40 min at 37°C to 
allow substrate conversion. As a negative control for all 
experiments, an aliquot of Aldefluor-stained cells was 
immediately quenched with diethylaminobenzaldehyde 
(DEAB), a specific ALDH inhibitor. Cells were analyzed 
using the FITC channel on the FACS Canto. Data were 
analyzed with FlowJo software. The ALDH+ fraction was 
calculated based on the disappearance of that fraction in 
the presence of DEAB using the formula: ALDH+ fraction 
= ALDH+ percentage(-DEAB) - ALDH
+ percentage(+DEAB)
Mammosphere formation assay
Mammosphere formation assays were performed 
as described, but with addition of 0.5% methylcellulose 
to prevent cell aggregation [18]. 1,000 cells were seeded 
per well in ultra-low attachment 96-well plates with SCM. 
After incubation with test compounds for 6 days, the 
mammosphere numbers (diameter > 50 μm) were counted 
and photographed.
Self-renewal assay
Adherent cells were pretreated with compounds or 
0.1% DMSO for 4 days. 1,000 cells were dissociated and 
seeded in ultra-low attachment 96-well plates with 100 µl 
of SCM. Cells were seeded in parallel at the same density 
in 6-well plates. 6 days later, the primary mammospheres 
formed in 96-well plates were counted and photographed. 
The cells in 6-well plates were dissociated into single 
cells and seeded as next generation of mammospheres 
in both 96-well and 6-well plates without treatment. 
The mammosphere number was measured in different 
generations of spheres without treatment.
RNA extraction and quantitative real-time PCR 
(qRT-PCR)
Total RNA was isolated from cells or sphere-
containing pellets using the Nucleo Spin RNA kit 
(Macherey-Nagel AG) and cDNA synthesis was performed 
by the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). qRT-PCR was run in an Applied 
Biosystems 7900HT fast real-time PCR machine. qRT-
PCR reactions were carried out with SYBR Green PCR 
Master Mix (Applied Biosystems) and ATCB (β-actin) 
levels were used as controls. The mean cycle threshold 
value (Ct), normalized to the Ct value of the housekeeping 
gene (ATCB) was used to calculate gene expression 
values. Primers for human genes were custom-made 
oligonucleotide primers (Microsynth, Switzerland). Primer 
sequences are shown in Table S1. Data are given as 2−ΔΔCt.
In vivo liming dilution assay
Animal studies were carried out according to the 
ethical guidelines established by our Institution (ETH 
Zürich), under approved animal protocols (11/2012 and 
12/2015) by the Veterinäramt des Kantons Zürich. Mice 
were housed in microisolator cages and in pathogen free 
conditions. Surgical procedures were performed under 
anesthesia and all efforts were made to minimize suffering 
of the animals. 4T1-luc2 spheres were maintained in 
ultra-low attachment plates with SCM and pretreated 
for 6 days with benztropine mesylate (5 μM) or DMSO 
(0.1%) in vitro. Single cells were injected in 50 μl 1:1 
matrigel:DMEM/F12 solution into the fourth mammary fat 
pad of 8-week old female Balb/c mice (Janvier) at varying 
cell numbers ranging from 10 to 1,000 cells/mouse. The 
tumor-initiating frequency, determined four weeks after 
injection, was used for calculation of frequency of BCSCs 
using the extreme limiting dilution assay (ELDA) webtool 
(http://bioinf.wehi.edu.au/software/elda) as described 
previously [52].
Statistics
Data are represented as mean±SD. Statistical 
tests were performed with GraphPad Prism V5.0 (San 
Diego, CA). A two-tailed Student’s t-test was used for 
comparisons of continuous variables between two groups. 
One-way ANOVA with Tukey or Dunnett post tests or 
two-way ANOVA was used when three or more groups 
were compared.
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